Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
APYX

APYX - Apyx Medical Corp Stock Price, Fair Value and News

2.14USD+0.12 (+5.94%)Market Closed
Watchlist

Market Summary

USD2.14+0.12
Market Closed
5.94%

APYX Stock Price

View Fullscreen

APYX RSI Chart

APYX Valuation

Market Cap

74.1M

Price/Earnings (Trailing)

-4.89

Price/Sales (Trailing)

1.47

EV/EBITDA

-3.93

Price/Free Cashflow

-9.08

APYX Price/Sales (Trailing)

APYX Profitability

EBT Margin

-35.11%

Return on Equity

-45.45%

Return on Assets

-25.49%

Free Cashflow Yield

-11.02%

APYX Fundamentals

APYX Revenue

Revenue (TTM)

50.3M

Rev. Growth (Yr)

31.4%

Rev. Growth (Qtr)

-11.74%

APYX Earnings

Earnings (TTM)

-15.2M

Earnings Growth (Yr)

19.69%

Earnings Growth (Qtr)

-365.69%

Breaking Down APYX Revenue

Last 7 days

-7.9%

Last 30 days

4.5%

Last 90 days

-3.3%

Trailing 12 Months

-30.5%

How does APYX drawdown profile look like?

APYX Financial Health

Current Ratio

4.87

Debt/Equity

0.27

Debt/Cashflow

-0.84

APYX Investor Care

Shares Dilution (1Y)

0.13%

Diluted EPS (TTM)

-0.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202344.2M47.4M50.3M0
202252.4M51.4M48.7M44.5M
202131.4M38.3M43.2M48.5M
202027.6M25.3M24.6M27.7M
201918.8M21.8M25.7M28.2M
201812.0M13.4M14.4M16.6M
201730.5M23.5M16.1M10.2M
201631.2M33.2M35.4M36.6M
201527.3M27.7M28.7M29.5M
20148.0M14.4M20.8M27.7M
201326.6M25.2M13.4M1.6M
201226.0M26.6M27.0M27.7M
201124.8M25.7M25.5M25.4M
201026.3M25.6M24.9M24.2M
200900027.0M

Tracking the Latest Insider Buys and Sells of Apyx Medical Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 12, 2023
hill matthew c
bought
5,475
2.19
2,500
chief financial officer
Nov 14, 2023
goodwin charles d. ii
bought
78,500
1.57
50,000
chief executive officer
Jul 12, 2023
waldman lawrence
acquired
15,853
2.97
5,338
-
Jun 26, 2023
hornsby todd
acquired
26,550
1.77
15,000
executive vice president
Jun 26, 2023
hornsby todd
sold
-113,400
7.56
-15,000
executive vice president
Jun 06, 2023
geraghty michael
acquired
27,900
2.79
10,000
-
Aug 29, 2022
goodwin charles d. ii
bought
70,067
5.96319
11,750
chief executive officer
Jul 11, 2022
citronowicz moshe
acquired
76,200
2.54
30,000
sr. v.p. of operations

1–10 of 27

Which funds bought or sold APYX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
new
-
73,491
73,491
-%
Feb 15, 2024
HORIZON KINETICS ASSET MANAGEMENT LLC
unchanged
-
-356,700
1,611,300
0.03%
Feb 15, 2024
BARCLAYS PLC
sold off
-100
-46,000
-
-%
Feb 14, 2024
Archon Capital Management LLC
unchanged
-
-2,002,180
9,044,320
2.24%
Feb 14, 2024
ALGERT GLOBAL LLC
sold off
-100
-50,000
-
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
reduced
-25.55
-314,645
491,211
-%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
new
-
33,531
33,531
-%
Feb 14, 2024
RTW INVESTMENTS, LP
reduced
-42.27
-2,999,000
2,688,020
0.04%
Feb 14, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-54,803
-
-%
Feb 14, 2024
Squarepoint Ops LLC
added
60.2
78,047
328,485
-%

1–10 of 47

Are Funds Buying or Selling APYX?

Are funds buying APYX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APYX
No. of Funds

Unveiling Apyx Medical Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
divisadero street capital management, lp
0.0%
0
SC 13G/A
Feb 14, 2024
pura vida investments, llc
0.23%
80,000
SC 13G/A
Feb 14, 2024
rtw investments, lp
3.0%
1,025,963
SC 13G/A
Feb 13, 2024
archon capital management llc
9.96%
3,452,030
SC 13G/A
Feb 07, 2024
hirschman orin
5.9%
2,040,540
SC 13G/A
Feb 02, 2024
cowen financial products llc
-
0
SC 13G/A
Jan 23, 2024
royce & associates lp
6.23%
2,158,900
SC 13G
Jan 23, 2024
royce & associates lp
6.23%
2,158,900
SC 13G/A
Aug 14, 2023
hirschman orin
5.4%
1,884,281
SC 13G
Jun 13, 2023
hirschman orin
4.9%
1,686,476
SC 13G/A

Recent SEC filings of Apyx Medical Corp

View All Filings
Date Filed Form Type Document
Feb 21, 2024
8-K
Current Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
SC 13G/A
Major Ownership Report
Jan 23, 2024
SC 13G
Major Ownership Report
Jan 23, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
8-K
Current Report

Peers (Alternatives to Apyx Medical Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.1B
40.1B
0.08% 5.41%
36.19
5.16
-8.12% -17.45%
70.3B
19.5B
1.90% -2.48%
56
3.61
4.02% -22.04%
24.2B
3.8B
13.67% -2.23%
66.83
6.37
-1.48% -28.97%
21.3B
14.9B
3.05% 1.38%
8.03
1.43
2.01% 209.17%
MID-CAP
10.0B
12.7B
2.56% -12.12%
22.51
0.79
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.59
3.72
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.84
2.68
4.97% 18.89%
7.1B
3.9B
-8.15% -6.44%
-32.48
1.81
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-287.71
10.08
42.19% 84.12%
2.6B
6.6B
-4.32% -4.67%
13.13
0.4
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.41
0.33
7.95% -543.98%
363.5M
163.3M
8.18% -20.52%
-14.79
2.23
7.14% -56.09%
238.7M
329.5M
3.17% -52.24%
-16.91
0.72
0.49% 64.22%
74.1M
50.3M
4.50% -30.54%
-4.89
1.47
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.37
1.19
5.77% 8.23%

Apyx Medical Corp News

Latest updates
CNN17 hours ago

Apyx Medical Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-11.7%11,976,00013,569,00012,142,00012,611,0009,114,00010,292,00012,493,00016,824,00011,831,00011,224,0008,638,00011,464,0006,954,0004,296,0004,997,0008,382,0007,575,0006,649,0005,629,0005,845,0003,672,000
Gross Profit-14.0%7,978,0009,279,0007,573,0008,241,0005,757,0006,914,0008,219,00012,151,0008,056,0007,534,0005,860,0007,701,0004,725,0002,094,0002,984,0005,563,0005,294,0004,674,0003,563,0003,556,0002,521,000
Operating Expenses-4.5%12,615,00013,206,00013,184,00014,174,00011,539,00012,890,00014,090,00013,843,00012,024,00011,577,00010,605,0009,754,0009,096,0008,261,00010,476,00011,524,00010,050,0009,096,0009,293,0009,391,0005,309,000
  S&GA Expenses-10.0%4,841,0005,378,0005,255,0005,809,0004,671,0004,539,0005,465,0006,021,0004,611,0004,261,0003,724,0002,996,0002,706,0002,189,0003,796,0003,870,0003,836,0003,037,0002,957,0003,186,0001,898,000
  R&D Expenses6.4%1,276,0001,199,0001,121,0001,255,0001,061,0001,070,0001,158,000947,0001,175,0001,084,0001,115,000918,0001,047,000975,000980,0001,097,0001,016,000888,000730,000610,000613,000
EBITDA Margin13.0%-0.31-0.36-0.49-0.49-0.37-0.32-0.29-0.29-0.32-0.37-0.52-0.67---------
Interest Expenses7.7%585,000543,000234,0003,0001,0003,0008,0001,0003,0002,0004,0007,00025,0008,0006,0008,000----1,000105,000
Income Taxes-581.8%-318,00066,000-2,267,000151,00050,00096,00070,000134,00073,000107,00066,000-391,000-715,000-1,492,000-4,905,000-383,000171,00076,0006,000-1,523,000-2,408,000
Earnings Before Taxes-423.9%-4,993,000-953,000-5,799,000-5,914,000-5,745,000-5,354,000-5,898,000-1,876,000-4,161,000-3,944,000-4,839,000-1,922,000-4,449,000-6,182,000-6,856,000-5,816,000-4,199,000-4,219,000-5,602,000-5,435,000-3,551,000
EBT Margin9.5%-0.35-0.39-0.52-0.51-0.39-0.34-0.30-0.31-0.34-0.40-0.55-0.70---------
Net Income-365.7%-4,629,000-994,000-3,483,000-6,049,000-5,764,000-5,426,000-5,945,000-2,003,000-4,222,000-4,046,000-4,901,000-1,527,000-3,728,000-4,690,000-1,951,000-5,433,000-4,370,000-4,295,000-5,608,000-3,912,00068,469,000
Net Income Margin12.3%-0.30-0.34-0.47-0.52-0.39-0.34-0.31-0.31-0.34-0.37-0.47-0.43---------
Free Cashflow170.1%3,489,000-4,975,000-1,991,000-4,692,000-5,548,000-6,273,000-4,797,000-118,000-3,775,000-5,035,000-2,244,000-1,405,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-4.8%59.0062.0057.0052.0055.0059.0063.0069.0068.0070.0071.0074.0075.0078.0082.0085.0087.0089.0092.0096.00113
  Current Assets-5.2%50.0053.0053.0043.0046.0051.0055.0061.0060.0062.0063.0066.0068.0070.0074.0077.0079.0082.0085.0090.00107
    Cash Equivalents19.5%22.0019.0016.0010.0015.0020.0026.0031.0031.0035.0040.0042.0044.0046.0051.0059.0062.0067.0032.0017.0041.00
  Inventory1.1%11.0011.0011.0012.0012.0010.007.007.006.005.004.004.005.005.006.005.007.006.006.005.006.00
  Net PPE-1.2%2.002.002.007.007.007.007.007.006.006.007.007.006.006.007.007.007.006.006.006.006.00
  Goodwill--------------------0.000.00
Liabilities0.6%26.0026.0021.0014.0013.0013.0013.0015.0013.0012.0011.0010.0011.0011.0012.0013.0010.008.009.009.0023.00
  Current Liabilities-45.9%10.0019.0019.0012.0011.0011.0012.0013.0012.0011.0010.009.0010.0010.0011.0012.009.008.009.009.0022.00
  Long Term Debt-9.00--------------------
    LT Debt, Current-100.0%-9.009.00------------------
    LT Debt, Non Current-9.00--------------------
Shareholder's Equity-9.2%33.0037.0036.0038.0042.0046.0050.0054.0055.0058.0060.0064.0064.0067.0070.0071.0076.0079.0083.0087.0091.00
  Retained Earnings-11.5%-44.84-40.21-39.22-35.73-29.69-23.92-18.50-12.55-10.55-6.33-2.283.004.008.0013.0015.0020.0024.0029.0034.0039.00
  Additional Paid-In Capital1.8%78.0077.0075.0073.0072.0070.0068.0066.0065.0064.0062.0061.0060.0059.0058.0057.0056.0055.0054.0053.0052.00
Accumulated Depreciation---3.005.005.005.005.005.005.005.005.005.005.005.005.004.00-----
Shares Outstanding0.0%35.0035.0035.0035.0035.0034.0034.0034.0034.0034.0034.0034.00---------
Minority Interest73.7%0.000.000.000.000.000.000.000.000.000.000.000.000.00--------
Float------202---354---190---227---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations176.0%3,663-4,819-1,881-4,550-5,360-5,872-4,518214-3,605-5,006-2,052-1,017-2,616-5,026-7,407-3,251-4,549-5,586-5,089-18,046-1,154
  Share Based Compensation-8.8%1,3511,4821,3671,6411,6921,7141,6501,3411,1841,3691,1941,0011,0631,0971,0499875438561,195986489
Cashflow From Investing-102.4%-1747,111-110-142-188-401-279-332-170-29.00-192-388-9.00-94.00-90.00-225-55840,48320,841-6,15835,791
Cashflow From Financing256.5%16446.008,112-10.001272.0098.00-39.00-33.00157-61.00-134109-63.0015.00-5.0037.0048.0067.00137-2,509

APYX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Sales$ 11,976$ 9,114$ 37,687$ 31,899
Cost of sales3,9983,35712,85711,009
Gross profit7,9785,75724,83020,890
Other costs and expenses:    
Research and development1,2761,0613,5963,289
Professional services1,8311,9365,1656,611
Salaries and related costs4,6673,87114,77013,944
Selling, general and administrative4,8414,67115,47414,675
Total other costs and expenses12,61511,53939,00538,519
Gain on sale-leaseback002,6920
Loss from operations(4,637)(5,782)(11,483)(17,629)
Interest income2487347893
Interest expense(585)(1)(1,362)(12)
Other (expense) income, net(19)(35)622551
Total other (expense) income, net(356)37(262)632
Loss before income taxes(4,993)(5,745)(11,745)(16,997)
Income tax (benefit) expense(318)50(2,519)216
Net loss(4,675)(5,795)(9,226)(17,213)
Net loss attributable to non-controlling interest(46)(31)(120)(78)
Net loss attributable to stockholders$ (4,629)$ (5,764)$ (9,106)$ (17,135)
Loss per share:    
Basic (in dollars per share)$ (0.13)$ (0.17)$ (0.26)$ (0.50)
Diluted (in dollars per share)$ (0.13)$ (0.17)$ (0.26)$ (0.50)

APYX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 22,134$ 10,192
Trade accounts receivable, net of allowance of $652 and $66812,64810,602
Income tax receivables07,545
Other receivables59699
Inventories, net of provision for obsolescence of $611 and $45711,28511,797
Prepaid expenses and other current assets3,4872,737
Total current assets50,15042,972
Property and equipment, net2,0936,761
Operating lease right-of-use assets5,274710
Finance lease right-of-use assets74115
Other assets1,8551,217
Total assets59,44651,775
Current liabilities:  
Accounts payable2,0502,669
Accrued expenses and other current liabilities7,9148,928
Current portion of operating lease liabilities310216
Current portion of finance lease liabilities2037
Total current liabilities10,29411,850
Term loan, net9,0090
Long-term operating lease liabilities4,992470
Long-term finance lease liabilities5873
Long-term contract liabilities1,3261,408
Other liabilities181181
Total liabilities25,86013,982
EQUITY  
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023, and 34,597,822 issued and outstanding as of December 31, 20223535
Additional paid-in capital78,15473,282
Accumulated deficit(44,841)(35,735)
Total stockholders’ equity33,34837,582
Non-controlling interest238211
Total equity33,58637,793
Total liabilities and equity$ 59,446$ 51,775
APYX
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and laparoscopic surgical procedures. The company's Helium Plasma Technology products are marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. It also offers hand pieces for open and laparoscopic procedures, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
 CEO
 WEBSITEwww.apyxmedical.com
 EMPLOYEES276

Apyx Medical Corp Frequently Asked Questions


What is the ticker symbol for Apyx Medical Corp? What does APYX stand for in stocks?

APYX is the stock ticker symbol of Apyx Medical Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apyx Medical Corp (APYX)?

As of Thu Feb 22 2024, market cap of Apyx Medical Corp is 74.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers.

What is the fair value of APYX stock?

You can check APYX's fair value in chart for subscribers. The fair value of Apyx Medical Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Apyx Medical Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APYX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Apyx Medical Corp a good stock to buy?

The fair value guage provides a quick view whether APYX is over valued or under valued. Whether Apyx Medical Corp is cheap or expensive depends on the assumptions which impact Apyx Medical Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APYX.

What is Apyx Medical Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, APYX's PE ratio (Price to Earnings) is -4.89 and Price to Sales (PS) ratio is 1.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APYX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Apyx Medical Corp's stock?

In the past 10 years, Apyx Medical Corp has provided -0.036 (multiply by 100 for percentage) rate of return.